Publications by authors named "C Assorgi"
(1) Background/Objectives: Nail psoriasis (NP) is a chronic and difficult-to-treat disease, which causes significant social stigma and impairs the patients' quality of life. Moreover, nail psoriasis is a true therapeutic challenge for clinicians. The presence of nail psoriasis can be part of a severe form of psoriasis and can have predictive value for the development of psoriatic arthritis.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to gather real-world data on the use of bimekizumab for treating moderate-to-severe plaque psoriasis in patients aged 65 and older, an age group often underrepresented in clinical trials.
- Conducted in 33 dermatological clinics in Italy, 98 elderly patients were treated with bimekizumab while collecting clinical and demographic data to monitor their progress and any adverse events over 36 weeks.
- Results showed significant improvements in psoriasis symptoms, with PASI scores dropping substantially after treatment, and a majority of patients achieving PASI75 or higher by weeks 16 and 36.
Article Synopsis
- * Biologics, especially IL-17 and IL-23 inhibitors, have been effective in treating psoriatic lesions, including challenging locations.
- * This case series presents the first real-life data showing the quick and successful treatment of facial psoriasis in six patients using bimekizumab, even though previous studies didn't specifically address facial lesions.
Background: The recent introduction of biological drugs specifically targeting the interleukins involved in psoriasis pathogenesis revolutionized the therapeutic scenario of moderate to severe forms of psoriasis. Among these, risankizumab, an anti-IL-23, was shown to be effective both in clinical trials and real-life experiences. However, data on its use on very severe forms of psoriasis, defined by a Psoriasis Area Severity Index (PASI) of at least 30, are scant.
View Article and Find Full Text PDF